Kingswood Wealth Advisors LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 57.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,065 shares of the biopharmaceutical company's stock after selling 1,431 shares during the period. Kingswood Wealth Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $759,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock valued at $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Swiss National Bank increased its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company's stock valued at $338,079,000 after acquiring an additional 2,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company's stock worth $316,957,000 after purchasing an additional 3,866 shares in the last quarter. Institutional investors own 83.31% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on REGN shares. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $1,004.57.
View Our Latest Research Report on REGN
Regeneron Pharmaceuticals Trading Down 0.3 %
REGN stock traded down $1.92 during trading on Thursday, hitting $685.35. 388,701 shares of the company traded hands, compared to its average volume of 864,346. The company has a 50-day moving average of $723.36 and a 200-day moving average of $928.61. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The firm has a market capitalization of $75.31 billion, a PE ratio of 16.96, a P/E/G ratio of 1.59 and a beta of 0.10.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
